...
首页> 外文期刊>Internal medicine journal >Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel
【24h】

Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel

机译:澳大利亚医护人员安全处理单克隆抗体治疗癌症的共识性指南

获取原文
获取原文并翻译 | 示例
           

摘要

These consensus guidelines provide recommendations for the safe handling of monoclonal antibodies. Definitive recommendations are given for the minimum safe handling requirements to protect healthcare personnel. The seven recommendations cover: (i) appropriate determinants for evaluating occupational exposure risk; (ii) occupational risk level compared with other hazardous and non-hazardous drugs; (iii) stratification of risk based on healthcare personnel factors; (iv) waste products; (v) interventions and safeguards; (vi) operational and clinical factors and (vii) handling recommendations. The seventh recommendation includes a risk assessment model and flow chart for institutions to consider and evaluate clinical and operational factors unique to individual healthcare services. These guidelines specifically evaluated monoclonal antibodies used in the Australian cancer clinical practice setting; however, the principles may be applicable to monoclonal antibodies used in non-cancer settings. The guidelines are only applicable to parenterally administered agents.
机译:这些共识指南为安全处理单克隆抗体提供了建议。给出了针对最低安全处理要求的明确建议,以保护医护人员。七项建议包括:(i)评估职业接触风险的适当决定因素; (ii)与其他危险和非危险药物相比的职业风险水平; (iii)根据医护人员因素对风险进行分层; (iv)废物; (v)干预措施和保障措施; (vi)操作和临床因素以及(vii)处理建议。第七项建议包括风险评估模型和流程图,供机构考虑和评估个人医疗服务独有的临床和操作因素。这些指南专门评估了澳大利亚癌症临床实践中使用的单克隆抗体。但是,该原理可能适用于非癌症环境中使用的单克隆抗体。该准则仅适用于胃肠外给药的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号